[go: up one dir, main page]

NO20073722L - Farmasoystiske sammensetniger omfattende bendamustin - Google Patents

Farmasoystiske sammensetniger omfattende bendamustin

Info

Publication number
NO20073722L
NO20073722L NO20073722A NO20073722A NO20073722L NO 20073722 L NO20073722 L NO 20073722L NO 20073722 A NO20073722 A NO 20073722A NO 20073722 A NO20073722 A NO 20073722A NO 20073722 L NO20073722 L NO 20073722L
Authority
NO
Norway
Prior art keywords
bendamustine
pharmaceutical
compositions
present
pharmaceutical formulations
Prior art date
Application number
NO20073722A
Other languages
English (en)
Other versions
NO343659B1 (no
Inventor
Jason Edward Brittain
Joe Craig Franklin
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36678237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20073722(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of NO20073722L publication Critical patent/NO20073722L/no
Publication of NO343659B1 publication Critical patent/NO343659B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer farmasøytiske formuleringer av lyofilisert bendamustin egnet for farmasøytisk anvendelse. Foreliggende oppfinnelse tilveiebringer videre fremgangsmåter for fremstilling av lyofilisert bendamustin. De farmasøytiske formuleringene kan bli anvendt for en hvilken som helst sykdom som er sensitiv for behandling med bendamustin, så som neoplastiske sykdommer.
NO20073722A 2005-01-14 2007-07-18 Farmasøytiske sammensetning omfattende bendamustin og fremgangsmåte for fremstilling av en lyofilisert farmasøytisk sammensetning. NO343659B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64435405P 2005-01-14 2005-01-14
US11/330,868 US8436190B2 (en) 2005-01-14 2006-01-12 Bendamustine pharmaceutical compositions
PCT/US2006/001308 WO2006076620A2 (en) 2005-01-14 2006-01-13 Bendamustine pharmaceutical compositions for lyophilisation

Publications (2)

Publication Number Publication Date
NO20073722L true NO20073722L (no) 2007-09-27
NO343659B1 NO343659B1 (no) 2019-04-29

Family

ID=36678237

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073722A NO343659B1 (no) 2005-01-14 2007-07-18 Farmasøytiske sammensetning omfattende bendamustin og fremgangsmåte for fremstilling av en lyofilisert farmasøytisk sammensetning.

Country Status (19)

Country Link
US (9) US8436190B2 (no)
EP (2) EP2574334A1 (no)
JP (3) JP2008526991A (no)
KR (4) KR20160098530A (no)
CN (1) CN102078305B (no)
AR (1) AR052877A1 (no)
AU (1) AU2006204817B2 (no)
BR (1) BRPI0606332A2 (no)
CA (1) CA2593582A1 (no)
EA (1) EA013324B1 (no)
ES (1) ES2405611T3 (no)
IL (1) IL184394A0 (no)
MX (1) MX2007008562A (no)
MY (1) MY157661A (no)
NO (1) NO343659B1 (no)
NZ (1) NZ556435A (no)
SG (1) SG158870A1 (no)
TW (1) TWI380830B (no)
WO (1) WO2006076620A2 (no)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
WO2007014278A2 (en) 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. B-cell reduction using cd37-specific and cd20-specific binding molecules
US20090082416A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched bendamustine
CA2702243C (en) * 2007-10-09 2016-06-21 Us Worldmeds Llc Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents
AR072777A1 (es) * 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
BRPI0911377A8 (pt) * 2008-04-11 2017-12-05 Trubion Pharmaceuticals Inc Imunoterápico de cd7 e combinação com quimioterápico bifuncional deste
EP2326306A1 (en) * 2008-09-25 2011-06-01 Cephalon, Inc. Liquid formulations of bendamustine
EP2350665A4 (en) * 2008-11-13 2012-06-06 Univ Indiana Res & Tech Corp COMBINED USE OF BENDAMUSTIN, DOXORUBICIN AND BORTEZOMIB FOR THE TREATMENT OF MULTIPLE MYELOMES
UA107186C2 (xx) * 2008-12-03 2014-12-10 Тверді форми дозування бендамустину
KR101688038B1 (ko) * 2008-12-03 2016-12-20 아스텔라스 도이칠란트 게엠베하 벤다무스틴의 경구 투약 형태
CN102281877B (zh) * 2009-01-15 2014-07-23 赛福伦公司 苯达莫司汀的游离碱形式
DK2389375T3 (en) 2009-01-23 2015-08-24 Euro Celtique Sa Hydroxamsyrederivater
RU2591804C2 (ru) 2009-02-25 2016-07-20 Супратек Фарма, Инк. Композиции бендамустина и циклополисахарида
WO2010126676A1 (en) * 2009-04-28 2010-11-04 Cephalon, Inc. Oral formulations of bendamustine
WO2010144675A1 (en) 2009-06-10 2010-12-16 Plus Chemicals Sa Polymorphs of bendamustine hcl and processes for preparation thereof
US8389558B2 (en) * 2009-07-20 2013-03-05 Supratek Pharma Inc. Bendamustine amphiphilic anionic compositions
US20110015245A1 (en) * 2009-07-20 2011-01-20 Valery Alakhov Bendamustine amphiphilic cationic compositions
DK3158991T3 (da) * 2010-01-28 2021-06-14 Eagle Pharmaceuticals Inc Formuleringer af bendamustin
WO2011103150A2 (en) * 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
JO3659B1 (ar) * 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
MY173873A (en) 2010-06-02 2020-02-25 Astellas Deutschland Gmbh Oral dosage forms of bendamustine
AU2011279402A1 (en) * 2010-07-13 2013-01-31 Cephalon, Inc. Improved methods for the sterilization of bendamustine
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
EP2667868A4 (en) * 2011-01-25 2014-12-10 Reddys Lab Ltd Dr Benda MUSTIN FORMULATIONS
SG192671A1 (en) * 2011-02-09 2013-09-30 Glaxosmithkline Llc Lyophilized formulations
WO2012112940A1 (en) 2011-02-18 2012-08-23 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
MX365393B (es) * 2011-09-13 2019-05-31 Pharmacyclics Llc Formulaciones de inhibidor de histona deacetilasa en combinación con bendamustina y usos de las mismas.
CN104011029B (zh) 2011-09-26 2016-06-08 费森尤斯卡比肿瘤学有限公司 一种制备盐酸苯达莫司汀的改进方法
WO2013102920A1 (en) 2011-11-18 2013-07-11 Astron Research Limited Stable lyophilized formulation of bendamustine
WO2013112762A1 (en) * 2012-01-24 2013-08-01 Innopharma, Inc. Bendamustine compositions and methods therefore
AR092790A1 (es) * 2012-02-01 2015-05-06 Euro Celtique Sa Derivados bencimidazolicos del acido hidroxamico
US9872873B2 (en) 2012-02-06 2018-01-23 Fresenius Kabi Oncology Limited Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis
CA2864118A1 (en) * 2012-02-14 2013-08-22 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
EP4360621A3 (en) 2012-03-20 2024-05-22 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
DK2827863T3 (en) 2012-03-20 2019-04-23 Eagle Pharmaceuticals Inc LIQUID COMPOSITION FOR USE IN A PROCEDURE FOR TREATING BENDAMUSTIN-RESPONSIVE CONDITIONS OF PATIENTS REQUIRING REDUCED VOLUMES FOR ADMINISTRATION
WO2013148919A1 (en) 2012-03-30 2013-10-03 The Regents Of The University Of Colorado, A Body Corporate Treatment of multiple myeloma
US9801859B2 (en) * 2012-09-18 2017-10-31 Innopharma Licensing, Llc Bendamustine formulations
US9452988B2 (en) 2012-11-12 2016-09-27 Ignyta, Inc. Bendamustine derivatives and methods of using same
ES2564274T3 (es) 2012-11-19 2016-03-21 Oncotec Pharma Produktion Gmbh Procedimiento para la preparación de una composición liofilizada
CN103860482B (zh) * 2012-12-12 2016-08-24 海口市制药厂有限公司 一种盐酸苯达莫司汀冻干粉针剂的制备方法、其产品及用途
CN103040769A (zh) * 2013-02-05 2013-04-17 南京碧迪可医药科技有限公司 一种稳定的诺卡沙星粉针冻干剂
EP2958554B1 (en) 2013-02-19 2018-06-06 Synthon BV Stable compositions of bendamustine
WO2014170769A2 (en) * 2013-04-15 2014-10-23 Shilpa Medicare Limited Bendamustine lyophilized pharmaceutical compositions
ITMI20131013A1 (it) * 2013-06-19 2014-12-20 Chemi Spa Formulazioni liofilizzate di bendamustina cloridrato
JP2016153374A (ja) * 2013-06-25 2016-08-25 シンバイオ製薬株式会社 炎症性疾患を治療又は予防するための医薬組成物
CN103351347A (zh) * 2013-07-29 2013-10-16 东南大学 盐酸苯达莫司汀杂质dce的制备方法
AU2014311570C1 (en) * 2013-08-27 2018-08-02 Vasilios VOUDOURIS Bendamustine pharmaceutical compositions
US20150087681A1 (en) * 2013-09-25 2015-03-26 Pranav Patel Bendamustine HCL Stable Lyophilized Formulations
US20160235717A1 (en) * 2013-10-11 2016-08-18 Luitpold Pharmaceuticals, Inc. Bendamustine pharmaceutical compositions
IN2014CH00151A (no) * 2014-01-13 2015-07-17 Hetero Research Foundation
MX382476B (es) 2014-03-13 2025-03-13 Vasilios Voudouris Dispersiones solidas de bendamustina e infusion continua.
KR20170008252A (ko) 2014-05-09 2017-01-23 아우로메딕스 파마 엘엘씨 사이클로포스파미드 액상 농축 제제
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
EP2985038A1 (en) 2014-08-12 2016-02-17 Azad Pharma AG Lyophilized API preparation
US10342769B2 (en) 2014-11-14 2019-07-09 Navinta Iii Inc Carmustine pharmaceutical composition
US9603930B2 (en) 2014-12-04 2017-03-28 Navinta, Llc Liquid bendamustine formulation
JP2018532806A (ja) * 2015-11-04 2018-11-08 キセラ バイオファーマシューティカルズ インコーポレイテッド デオキシコール酸およびその塩による蓄積脂肪の処置方法
US10905677B2 (en) 2016-08-31 2021-02-02 Navinta, Llc Bendamustine solution formulations
US11826466B2 (en) 2016-08-31 2023-11-28 Navinta, Llc Bendamustine solution formulations
WO2018068832A1 (en) 2016-10-11 2018-04-19 Euro-Celtique S.A. Hodgkin lymphoma therapy
US10688222B2 (en) 2016-11-21 2020-06-23 Warsaw Orthopedic, Inc. Lyophilized moldable implants containing an oxysterol
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
CA3108321A1 (en) 2018-08-17 2020-02-20 Hospira Australia Pty Ltd Liquid bendamustine pharmaceutical compositions
US11730815B2 (en) 2018-11-26 2023-08-22 Good Health, Llc Stable liquid pharmaceutical compositions comprising bendamustine
CN113365624A (zh) 2018-12-18 2021-09-07 萌蒂制药国际有限公司 用于治疗淋巴瘤或t-细胞恶性疾病的化合物
US11406598B2 (en) 2019-09-20 2022-08-09 Nivagen Pharmaceuticals, Inc. Lyophilized compositions of phenobarbital sodium salt
CN110638765A (zh) * 2019-11-08 2020-01-03 江苏食品药品职业技术学院 一种卡莫司汀冻干工艺
US20240148696A1 (en) 2022-10-25 2024-05-09 Softkemo Pharma Inc. Lyophilized bendamustine-cyclodextrin composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD159289A1 (de) * 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD80967A (no)
DE80967C (no)
DE159289C (no) 1903-10-08 1905-03-16
DE34727C (de) Ch. H. TH. HAVEMANN in Paris, 16 rue Bleue Verfahren zur direkten Gewinnung metallischen Bleis
DE1354952U (no)
DD34727A1 (de) 1963-12-21 1964-12-28 Dietrich Krebs Verfahren zur Herstellung von 1-Stellung substituierten [5-Bis-(chloräthyl)-amino-benzimidazolyl-(2)]-alkancarbonsäuren
YU33730B (en) 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
US4012448A (en) 1976-01-15 1977-03-15 Stanford Research Institute Synthesis of adriamycin and 7,9-epiadriamycin
DD159877A1 (de) 1981-06-12 1983-04-13 Wolfgang Krueger Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
US5227374A (en) 1982-11-12 1993-07-13 Mead Johnson & Company Lyophilized cyclophosphamide
US4659699A (en) 1983-08-22 1987-04-21 Cetus-Ben Venue Therapeutics Process for freeze drying cyclophosphamide
US5183746A (en) 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
US5204335A (en) 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
NO873860L (no) * 1986-10-31 1988-05-02 Asta Pharma Ag Ifosfamid-lyofilisat og fremgangsmaate til deres fremstilling.
DE3907079A1 (de) 1988-03-19 1989-09-28 Asta Pharma Ag Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung
EP0334083B1 (de) 1988-03-19 1991-07-24 ASTA Pharma Aktiengesellschaft Ifosfamid-Mesna-Lyophilisat und Verfahren zu dessen Herstellung
US5036060A (en) 1988-07-25 1991-07-30 Fujisawa Usa, Inc. Cyclophosphamide
CA2001552C (en) 1988-11-14 1997-07-22 The Upjohn Company Cyclophosphamide - sodium bicarbonate lyophilizates
US5066647A (en) 1989-04-20 1991-11-19 Erbamont, Inc. Cyclophosphamide - alanine lyophilizates
DD293808A5 (de) 1990-04-23 1991-09-12 Zi Fuer Mikrobiologie Uns Experimentelle Therapie,De Verfahren zur herstellung von (5-[bis(2-chlorethyl)amino]-1-methyl-benzimidazolyl(2)ethansaeurealkylestern
US5268368A (en) 1991-05-17 1993-12-07 Erbamont, Inc. Cyclophosphamide--amino acid lyophilizates
US5227373A (en) 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
US5192743A (en) 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
PL174721B1 (pl) 1992-11-13 1998-09-30 Idec Pharma Corp Przeciwciało monoklonalne anty-CD20
US5418223A (en) 1993-05-20 1995-05-23 Erbamont, Inc. Method for lyophilization of cyclophosphamide and product
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
ATE187071T1 (de) 1993-10-27 1999-12-15 Upjohn Co Stabilisiertes prostaglandin e1
US5561121A (en) * 1993-11-09 1996-10-01 American Cyanamid Company Stable lyophilized thiotepa composition
US5854268A (en) * 1994-08-02 1998-12-29 Merck Sharp & Dohme, Ltd. Azetidine, pyrrolidine and piperidine derivatives
US5955504A (en) 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
DE19529057B4 (de) 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
JPH11511463A (ja) 1995-08-31 1999-10-05 スミスクライン・ビーチャム・コーポレイション インターロイキン変換酵素およびアポプトーシス
PT780386E (pt) 1995-12-20 2003-02-28 Hoffmann La Roche Inibidores de metaloprotease de matriz
US6261537B1 (en) * 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US6077850A (en) 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US20040072889A1 (en) 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
AU767586B2 (en) 1998-07-09 2003-11-20 Cephalon, Inc. Methods and compositions for the treatment of chronic lymphocytic leukemia
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US5972912A (en) 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6380210B1 (en) 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6545034B1 (en) 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
DE10016077A1 (de) 2000-03-31 2001-12-13 Cellcontrol Biomedical Lab Gmb Verfahren und Vorrichtung zum automatischen Nachweisen einer Wirkung eines zellbeeinflussenden Mittels auf lebende Zellen
US20040152672A1 (en) 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
US20040058956A1 (en) 2000-12-11 2004-03-25 Yohko Akiyama Pharmaceutical composition having an improved water solubility
CA2431322A1 (en) 2000-12-11 2002-06-20 Eiji Nara Medicinal compositions having improved absorbability
IL161335A0 (en) * 2001-10-15 2004-09-27 Hemoteq Gmbh Coating of stents for preventing restenosis
US6613927B1 (en) 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
DE10306724A1 (de) 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Vesikuläre Verkapselung von Bendamustin
US6780324B2 (en) 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
DE60319681T2 (de) 2002-03-22 2009-03-12 Ludwig Maximilian Universität Zytokapazität-verfahren
EP1354952A1 (en) 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
WO2003086470A2 (en) 2002-04-17 2003-10-23 Deutsches Krebsforschungszentrum Smac-peptides as therapeutics against cancer and autoimmune diseases
US20040234575A1 (en) 2002-05-09 2004-11-25 Roland Horres Medical products comprising a haemocompatible coating, production and use thereof
WO2004012769A1 (en) 2002-08-02 2004-02-12 The Regents Of The University Of California Therapeutic inhibitionof protein kinases in cancer cells
US20040151774A1 (en) 2002-10-31 2004-08-05 Pauletti Giovanni M. Therapeutic compositions for drug delivery to and through covering epithelia
DE10304403A1 (de) 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
US7157551B2 (en) 2003-02-14 2007-01-02 Cephalon, Inc. Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers
RU2345772C2 (ru) * 2003-07-25 2009-02-10 Уайт Лиофилизированные композиции cci-779
RU2346996C2 (ru) 2004-06-29 2009-02-20 ЮРОПИЭН НИКЕЛЬ ПиЭлСи Усовершенствованное выщелачивание основных металлов
CN101933923A (zh) 2004-11-05 2011-01-05 赛福伦公司 癌症治疗
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
EP2326306A1 (en) 2008-09-25 2011-06-01 Cephalon, Inc. Liquid formulations of bendamustine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD159289A1 (de) * 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MAAS B: "Stabilität von Bendamustinhydrochlorid in Infusionsl sungen" PHARMAZIE, DIE, GOVI VERLAG, ESCHBORN, DE, vol. 49, no. 10, 1994, pages 775-777, Dated: 01.01.0001 *
SCASNAR V ET AL: "Radiochemical assay of stability of <14>C-cytostasan solutions during preparation and storage" JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY 1988 SWITZERLAND, vol. 121, no. 2, 1988, pages 489-497, Dated: 01.01.0001 *
WERNER W ET AL: "Hydrolyseprodukte des Cancerostaticums Cytostasan (Bendamustin)" PHARMAZIE, DIE, GOVI VERLAG, ESCHBORN, DE, vol. 42, no. 4, 1987, pages 272-273, Dated: 01.01.0001 *

Also Published As

Publication number Publication date
US8609863B2 (en) 2013-12-17
IL184394A0 (en) 2007-10-31
CN102078305A (zh) 2011-06-01
JP2013056902A (ja) 2013-03-28
MY157661A (en) 2016-07-15
MX2007008562A (es) 2007-09-07
KR20070094848A (ko) 2007-09-21
AU2006204817B2 (en) 2010-11-25
JP5726833B2 (ja) 2015-06-03
US20200237726A1 (en) 2020-07-30
US20130338205A1 (en) 2013-12-19
NO343659B1 (no) 2019-04-29
AR052877A1 (es) 2007-04-11
KR20170096221A (ko) 2017-08-23
WO2006076620A2 (en) 2006-07-20
US8895756B2 (en) 2014-11-25
US20180296534A1 (en) 2018-10-18
JP2013056901A (ja) 2013-03-28
US20130131131A1 (en) 2013-05-23
US8436190B2 (en) 2013-05-07
US20140148490A1 (en) 2014-05-29
AU2006204817A1 (en) 2006-07-20
KR101648495B1 (ko) 2016-08-17
CA2593582A1 (en) 2006-07-20
US20150374671A1 (en) 2015-12-31
US20130123316A1 (en) 2013-05-16
KR20180056804A (ko) 2018-05-29
TWI380830B (zh) 2013-01-01
NZ556435A (en) 2011-01-28
ES2405611T3 (es) 2013-05-31
KR20160098530A (ko) 2016-08-18
US20130041003A1 (en) 2013-02-14
EA013324B1 (ru) 2010-04-30
SG158870A1 (en) 2010-02-26
US8791270B2 (en) 2014-07-29
EP1863452B1 (en) 2013-04-03
BRPI0606332A2 (pt) 2009-11-17
JP5688195B2 (ja) 2015-03-25
WO2006076620A3 (en) 2006-12-28
EP1863452A2 (en) 2007-12-12
JP2008526991A (ja) 2008-07-24
US8461350B2 (en) 2013-06-11
TW200637614A (en) 2006-11-01
EP2574334A1 (en) 2013-04-03
US20060159713A1 (en) 2006-07-20
HK1116073A1 (en) 2008-12-19
EA200701511A1 (ru) 2007-12-28
CN102078305B (zh) 2014-05-28
KR101918188B1 (ko) 2018-11-14

Similar Documents

Publication Publication Date Title
NO20073722L (no) Farmasoystiske sammensetniger omfattende bendamustin
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
CL2012002497A1 (es) Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras.
CL2007003635A1 (es) Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer.
CL2007000806A1 (es) Compuestos derivados de heteropentaciclos sustituidos; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento del cancer.
BRPI0915084B8 (pt) composto, e, composição farmacêutica
CL2008001868A1 (es) Compuestos derivados de n-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas; composicion farmaceutica que comprende a dicho compuesto; y uso para el tratamiento de enfermedades inflamatorias del intestino, enfermedad alergica
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
CL2011002115A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 5-fenil-pirazin-2-ona, inhibidores de la tirosina-quinasa de bruton (btk); proceso de preparación de los compuestos, compuesto intermediario, composición farmacéutica y uso en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
CL2013001654A1 (es) Compuestos derivados de 6-amino-2-fenilamino-1h-bencimidazol-5-carboxamida; composicion farmaceutica; y su uso en el tratamiento y/o prevencion de las enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
MX377802B (es) Metodos y composiciones para trastornos del sueño y otros trastornos.
EA201500430A1 (ru) Соединения боронатного эфира и его фармацевтические составы
PA8784001A1 (es) Oxazolidinonas sustituidas y su uso
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
CL2011002300A1 (es) Compuestos derivados de 2,4-diamiropirimidinas 5-sustitudas inhibidoras de quinasa ptk2; preparaciones farmaceuticas; y su uso para el tratamiento y/o la prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes.
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
EA200801580A1 (ru) Новые производные пирониндола и способ их получения

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: CEPHALON, US